The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
US Generics grew 5% to Rs. 467 Crores for the quarter
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
The segment delivered strong sales growth of 20% YoY
Subscribe To Our Newsletter & Stay Updated
